secwatch.observer — SEC 8-K summary
======================================

Issuer:     Spyre Therapeutics, Inc. (SYRE)
CIK:        0001636282
Form:       8-K
Filed at:   2026-06-01T20:01:39+00:00
Accession:  0001636282-26-000075
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Spyre Therapeutics expands SPY003 license field beyond IBD with dosing restrictions until 2028-2030
--------------------------------------------------------------------------------

- License field expanded from inflammatory bowel disease to all human disease indications.
- Monotherapy dosing for non-IBD indications restricted until June 1, 2030; combination until June 1, 2028.
- Restrictions may terminate earlier upon a Material Transaction (change of control, asset sale) by June 1, 2028.
- Paragon receives non-exclusive license under Spyre's cross-license patents for retained IL-23 antibodies.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/0001636282-26-000075-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636282/000163628226000075/syre-20260529.htm
  HTML page:      https://secwatch.observer/filing/0001636282-26-000075

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer